Eagle Pharmaceuticals (EGRX) Holder Park West Asset Management Has Upped Its Stake by $6.79 Million; Rigel Pharmaceuticals (RIGL) Shareholder Ghost Tree Capital Trimmed Stake as Shares Rose

May 16, 2018 - By Michael Collier

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Logo

Peter S. Park increased its stake in Eagle Pharmaceuticals Inc (EGRX) by 14.1% based on its latest 2017Q4 regulatory filing with the SEC. Park West Asset Management Llc bought 128,054 shares as the company’s stock declined 2.46% with the market. The hedge fund run by Peter S. Park held 1.04M shares of the health care company at the end of 2017Q4, valued at $55.36 million, up from 908,220 at the end of the previous reported quarter. Park West Asset Management Llc who had been investing in Eagle Pharmaceuticals Inc for a number of months, seems to be bullish on the $979.14M market cap company. The stock increased 2.29% or $1.48 during the last trading session, reaching $66. About 201,867 shares traded. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has declined 36.05% since May 16, 2017 and is downtrending. It has underperformed by 47.60% the S&P500.

Ken Greenberg decreased its stake in Rigel Pharmaceuticals Inc (RIGL) by 25% based on its latest 2017Q4 regulatory filing with the SEC. Ghost Tree Capital Llc sold 275,000 shares as the company’s stock rose 8.02% while stock markets declined. The hedge fund run by Ken Greenberg held 825,000 shares of the health care company at the end of 2017Q4, valued at $3.20 million, down from 1.10M at the end of the previous reported quarter. Ghost Tree Capital Llc who had been investing in Rigel Pharmaceuticals Inc for a number of months, seems to be less bullish one the $639.60M market cap company. The stock decreased 0.51% or $0.02 during the last trading session, reaching $3.91. About 962,105 shares traded. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 9.91% since May 16, 2017 and is uptrending. It has underperformed by 1.64% the S&P500.

Park West Asset Management Llc, which manages about $1.77B and $2.19B US Long portfolio, decreased its stake in Par Pacific Holdings Inc (NYSEMKT:PARR) by 203,804 shares to 473,903 shares, valued at $9.14M in 2017Q4, according to the filing. It also reduced its holding in Clipper Rlty Inc by 60,275 shares in the quarter, leaving it with 626,510 shares, and cut its stake in Career Education Corp (NASDAQ:CECO).

More news for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) were recently published by: Streetinsider.com, which released: “Eagle (EGRX) Denied Unique Ryanodex J-Code – Mizuho” on May 07, 2018. Streetinsider.com‘s article titled: “Eagle Pharmaceuticals (EGRX) Misses Q1 EPS by 16c, Miss on Revenues” and published on May 10, 2018 is yet another important article.

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Eagle Pharma has $119 highest and $37.0 lowest target. $71.75’s average target is 8.71% above currents $66 stock price. Eagle Pharma had 25 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Monday, December 18 by Mizuho. RBC Capital Markets maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) rating on Monday, October 2. RBC Capital Markets has “Buy” rating and $81.0 target. On Sunday, November 5 the stock rating was maintained by RBC Capital Markets with “Buy”. Piper Jaffray maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) rating on Wednesday, July 29. Piper Jaffray has “Overweight” rating and $119 target. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has “Outperform” rating given on Thursday, November 3 by RBC Capital Markets. The firm has “Buy” rating given on Friday, February 26 by Mizuho. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) earned “Underperform” rating by Mizuho on Monday, January 9. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has “Sell” rating given on Thursday, October 26 by Mizuho. The rating was maintained by Piper Jaffray on Tuesday, July 25 with “Buy”. RBC Capital Markets maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) rating on Tuesday, May 10. RBC Capital Markets has “Outperform” rating and $78 target.

Among 6 analysts covering Rigel Pharmaceuticals (NASDAQ:RIGL), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rigel Pharmaceuticals has $11 highest and $3.25 lowest target. $6.79’s average target is 73.66% above currents $3.91 stock price. Rigel Pharmaceuticals had 29 analyst reports since August 8, 2015 according to SRatingsIntel. The firm has “Overweight” rating by Piper Jaffray given on Monday, June 13. As per Monday, September 4, the company rating was maintained by Jefferies. The rating was maintained by BMO Capital Markets on Wednesday, May 2 with “Outperform”. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has “Buy” rating given on Wednesday, April 18 by H.C. Wainwright. The company was maintained on Wednesday, April 4 by Jefferies. The rating was maintained by BMO Capital Markets with “Buy” on Monday, October 2. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has “Buy” rating given on Monday, November 6 by H.C. Wainwright. On Wednesday, August 31 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Friday, January 19. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Buy” rating by H.C. Wainwright on Tuesday, April 3.

Analysts await Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report earnings on August, 7. They expect $-0.16 EPS, 0.00% or $0.00 from last year’s $-0.16 per share. After $-0.17 actual EPS reported by Rigel Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -5.88% EPS growth.

More recent Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) news were published by: Seekingalpha.com which released: “Rigel Pharmaceuticals Is In Bargain Territory” on April 25, 2018. Also 247Wallst.com published the news titled: “Rigel Pharmaceuticals Gets No Boost From FDA Approval” on April 18, 2018. Seekingalpha.com‘s news article titled: “Rigel Gets A Surprise Approval For Tavalisse” with publication date: April 24, 2018 was also an interesting one.

Since April 20, 2018, it had 0 buys, and 1 insider sale for $20,550 activity.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>